Abstract
Background: Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed. The current leading hypotheses are based on the sensitization and activation of the trigeminovascular system.
Objective: To review the literature with focus on the effects of kynurenines (L-kynurenine and kynurenic acid) and pituitary adenylate cyclase-activating polypeptide on the regulation of the trigeminovascular system. Method: A literature search was conducted to identify preclinical and clinical publications (198 references) by using the keywords ‘kynurenines’, ‘pituitary adenylate cyclase-activating polypeptide’, and ‘migraine’ in the database of MEDLINE/PubMed up to 10 September 2016 for topical review. Additional filters used included ‘review’, ‘systematic review’, ‘original article’, and ‘English language’. Results: L-kynurenine and kynurenic acid act on the glutamatergic system at the level of the second-order nociceptive neurons in the trigeminal nucleus caudalis. Pituitary adenylate cyclase- activating polypeptide is released from the peripheral nerve endings of the trigeminal pseudounipolar neurons and causes vasodilation and mast cell degranulation, leading to consequent peripheral sensitization of the dural nociceptors. Centrally released pituitary adenylate cyclase-activating polypeptide in the trigeminal nucleus caudalis results in the central sensitization of the second-order neurons. The sensitization process leads to the characteristic features of migraine. Conclusion: L-kynurenine, kynurenic acid, and pituitary adenylate cyclase-activating polypeptide may have fundamental roles in the initiation of migraine headache attacks.Keywords: Glutamate, kynurenine, migraine, mode of action, pathomechanism, pituitary adenylate cyclaseactivating polypeptide.
Current Medicinal Chemistry
Title:Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects
Volume: 24 Issue: 13
Author(s): Janos Tajti, Delia Szok, Gabor Nagy-Grocz, Bernadett Tuka, Anna Petrovics-Balog, Jozsef Toldi and Laszlo Vecsei*
Affiliation:
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Semmelweis u. 6., H-6725, Szeged,Hungary
Keywords: Glutamate, kynurenine, migraine, mode of action, pathomechanism, pituitary adenylate cyclaseactivating polypeptide.
Abstract: Background: Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed. The current leading hypotheses are based on the sensitization and activation of the trigeminovascular system.
Objective: To review the literature with focus on the effects of kynurenines (L-kynurenine and kynurenic acid) and pituitary adenylate cyclase-activating polypeptide on the regulation of the trigeminovascular system. Method: A literature search was conducted to identify preclinical and clinical publications (198 references) by using the keywords ‘kynurenines’, ‘pituitary adenylate cyclase-activating polypeptide’, and ‘migraine’ in the database of MEDLINE/PubMed up to 10 September 2016 for topical review. Additional filters used included ‘review’, ‘systematic review’, ‘original article’, and ‘English language’. Results: L-kynurenine and kynurenic acid act on the glutamatergic system at the level of the second-order nociceptive neurons in the trigeminal nucleus caudalis. Pituitary adenylate cyclase- activating polypeptide is released from the peripheral nerve endings of the trigeminal pseudounipolar neurons and causes vasodilation and mast cell degranulation, leading to consequent peripheral sensitization of the dural nociceptors. Centrally released pituitary adenylate cyclase-activating polypeptide in the trigeminal nucleus caudalis results in the central sensitization of the second-order neurons. The sensitization process leads to the characteristic features of migraine. Conclusion: L-kynurenine, kynurenic acid, and pituitary adenylate cyclase-activating polypeptide may have fundamental roles in the initiation of migraine headache attacks.Export Options
About this article
Cite this article as:
Tajti Janos, Szok Delia, Nagy-Grocz Gabor, Tuka Bernadett, Petrovics-Balog Anna, Toldi Jozsef and Vecsei Laszlo*, Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects, Current Medicinal Chemistry 2017; 24 (13) . https://dx.doi.org/10.2174/0929867324666170227115019
DOI https://dx.doi.org/10.2174/0929867324666170227115019 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design A Meta-analysis and Systematic Review of Randomised Controlled Trials Comparing Cognitive Behavioural Therapy to Conventional Treatment of Osteoarthritis
Current Rheumatology Reviews Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Hypertension in Hemodialysis Patients
Current Hypertension Reviews Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Psychiatric Manifestations of Ehlers-Danlos Syndrome in Adolescents: A Case Report and Literature Review
Current Psychiatry Research and Reviews Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Tryptophan Catabolites and Migraine
Current Pharmaceutical Design Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial
Current Clinical Pharmacology Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research microRNAs to Monitor Pain-migraine and Drug Treatment
MicroRNA